Similar articles

• [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].

  Olsson AG. Olsson AG. Lakartidningen. 2006 Aug 30-Sep 5;103(35):2454-5. Lakartidningen. 2006. PMID: 17002160 Swedish. No abstract available.
• Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.

  Donnelly R. Donnelly R. Int J Clin Pract. 2007 Jul;61(7):1160-9. doi: 10.1111/j.1742-1241.2007.01396.x. Epub 2007 May 18. Int J Clin Pract. 2007. PMID: 17511791 Review.
• Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.

  Bajaj M, Jialal I. Bajaj M, et al. Metab Syndr Relat Disord. 2009 Apr;7(2):79-81. doi: 10.1089/met.2008.0092. Metab Syndr Relat Disord. 2009. PMID: 19351292 No abstract available.
• [Too positive comment on glitazones].

  Lindberg M. Lindberg M. Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733. Ugeskr Laeger. 2007. PMID: 17338040 Danish. No abstract available.
• [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].

  Hemmingsen B, Lund SS, Vaag A. Hemmingsen B, et al. Ugeskr Laeger. 2009 May 4;171(19):1598-602. Ugeskr Laeger. 2009. PMID: 19419642 Review. Danish.